Details of the Drug Combination

General Information of Drug Combination (ID: DC3DB6L)

• Drug Combination Name: Hepzato + TEM
• Indication: Amelanotic melanoma; Status: Investigative [1]
• Component Drugs:
  Hepzato (DM2AZPP): N.A.
  TEM (DMLNFWU): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MDA-MB-435
  Zero Interaction Potency (ZIP) Score: 1.3
  Bliss Independence Score: 2.44
  Loewe Additivity Score: 1.37
  LHighest Single Agent (HSA) Score: 0.66

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCXTN17	U251	Investigative	[4]
Astrocytoma	DC2TA3A	SNB-19	Investigative	[4]
Glioma	DCN17TL	SF-295	Investigative	[4]
Invasive ductal carcinoma	DCZ1CSG	T-47D	Investigative	[5]
Invasive ductal carcinoma	DCCBBXH	HS 578T	Investigative	[5]
Adenocarcinoma	DCF77QR	SW-620	Investigative	[1]
Amelanotic melanoma	DCGVE6T	M14	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.